On Tuesday (18th), Astrazeneca (AZN.US) (AZN.L) announced that its breast cancer drug Truqap combined with chemotherapy drug Paclitaxel treatment (CAPItello-290) did not meet the goal of improving overall survival in late-stage clinical trials.

Astrazeneca stated that triple-negative breast cancer is one of the most difficult-to-treat diseases due to the lack of known actionable biomarker targets, and chemotherapy-based treatment remains the mainstream approach.

Astrazeneca's British stocks remained steady in early trading, reporting 12,428 pence.